39例肝细胞腺瘤影像学特点分析*

doi:10.3969/j.issn.1672-5069.2026.04.033

Abstract

Abstract: Objective The aim of this study was to summarize imaging features of hepatocellular adenoma (HCA). Methods The clinical materials of 39 patients with HCA encountered in our hospital between May 2020 and March 2024 were reviewed. All patients underwent CT and MR scan. Histo-pathological typing was performed by immunohistochemistry and genotype sequencing. Results Of 39 patients with HCA in our series, inflammatory HCA (I-HCA), β-catenin-activated HCA (B-HCA), hepatocyte nuclear factor 1α-inactivated HCA (H-HCA) and unclassifled HCA (U-HCA) were found in 18 cases, 10 cases, 6 cases and 5 cases, respectively; percentage of low enhancement at delayed phase in I-HCA lesions was 55.6%, much higher than 10.0%(P<0.05) in H-HCA or 0.0%(P<0.05)in H-HCA or 0.0%(P<0.05)in U-HCA lesions; percentage of subcapsular enhancement in B-HCA lesions was 100.0%(P<0.05), much higher than 38.9%(P<0.05) in I-HCA or 10.0%(P<0.05)in H-HCA or 20.0%(P<0.05)in U-HCA; percentage of high signal at MR T1WI sequence in I-HCA was 72.2%, much higher than 10.0%(P<0.05) in H-HCA or 16.7%(P<0.05) in B-HCA or 0.0%(P<0.05)in U-HCA lesions; low signal intensity at T2WI sequence in H-HCA was more common, with a slight enhancement, gradually decreased, significantly different from other HCA types(P<0.05). Conclusion I-HCA is more common clinically, with a slight different imaging feature in different HCA types, which needs further summarization.

Key words: Hepatocellular adenoma, CT scan, Magnetic resonance imaging, Molecular typing

Zuo Renzhi, Wang Kaixuan, Ge Shang. Imaging feature of hepatocellular adenoma: An analysis of 39 cases[J]. Journal of Practical Hepatology, 2026, 29(4): 609-612.

References

[1] Poetter-Lang S, Ba-Ssalamah A, Bastati N, et al. Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course. Br J Radiol, 2024, 97(1163):1740-1754.
[2] Hashimoto S, Hasan MDN, Arif M, et al. Aberrantly expressed tRNA-val fragments can distinguish canine hepatocellular carcinoma from canine hepatocellular adenoma. Genes (Basel), 2024, 15(8):1024.
[3] Declaux G, Denis de Senneville B, Trillaud H, et al. Assessment of a multivariable model using MRI-radiomics, age and sex for the classification of hepatocellular adenoma subtypes. Res Diagn Interv Imaging, 2024, 10:100046.
[4] Cao JJ, Shen L, Yoon L, et al. Differentiation of hepatocellular adenoma subtypes and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI: An updated diagnostic algorithm. AJR, 2024, 223(4):e2431628.
[5] Alareer HSN, Jasim Taher H, Dinar Abdullah A. Dynamic contrast enhanced-MRI and apparentdiffusion coefficient quantitation for differentiate hepatocellular carcinoma from hepatocellular adenoma. Asian Pac J Cancer Prev, 2024, 25(3):931-937.
[6] Verde F, Ponsiglione A. Role of perfusion features in contrast-enhanced ultrasound differential diagnosis of hepatocellular adenoma and carcinoma: Far beyond the gray-scale ultrasound. J Clin Ultrasound, 2022, 50(2):222-223.
[7] Liu YH, Fan ZH, Yin SS, et al. Diagnostic value of color parametric imaging and contrast-enhanced ultrasound in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Clin Ultrasound, 2022, 50(2):216-221.
[8] Park HJ, Byun JH, Kang JH, et al. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma. Eur J Radiol, 2021, 139:109730.
[9] Nie P, Wang N, Pang J, et al. CT-based radiomics nomogram: A potential tool for differentiating hepatocellular adenoma from hepatocellular carcinoma in the noncirrhotic liver. Acad Radiol, 2021, 28(6):799-807.
[10] Cannella R, Borhani AA, Minervini MI, et al. Evaluation of texture analysis for the differential diagnosis of focal nodular hyperplasia from hepatocellular adenoma on contrast-enhanced CT images. Abdom Radiol (NY), 2019, 44(4):1323-1330.
[11] Abdullah AD, Amanpour-Gharaei B, Nassiri Toosi M, et al. Comparing texture analysis of apparent diffusion coefficient MRI in hepatocellular adenoma and hepatocellular carcinoma. Cureus, 2024, 16(1):e51443.
[12] 王鹏雁, 邵汇琳, 班新超, 等. 基于免疫组化的肝细胞腺瘤分型及临床病理学分析. 中华肝胆外科杂志, 2019, 25(7):509-512.
[13] Huang Z, Li Y, Chen W, et al. Insulin-like growth factor-1 deficiency caused by hepatocellular adenoma leads to growth arrest, primary amenorrhea and metabolic syndrome: a case report and 4 years follow up. BMC Endocr Disord, 2024, 24(1):188.
[14] Bu Y, Huang R, Gao J, et al. Whole-exome sequencing-based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma. Clin Exp Pharmacol Physiol, 2024, 51(7):e13901.
[15] Huang J, Xu D, Li A. Laparoscopic hepatectomy for hepatocellular adenoma using the hepatic vein as anatomic markers: How I do it (with video). Asian J Surg, 2024, 47(12):5143-5146.
[16] 潘豪, 陈小凤, 韩晶, 等. 肝细胞核因子1α失活型肝细胞腺瘤的MRI特征分析. 中华肝脏病杂志, 2023, 31(11):1192-1197.
[17] Iwabuchi S, Takahashi K,Kawaguchi K, et al. Phospholipase a2 group IIA is associated with inflammatory hepatocellular adenoma. Cancers (Basel), 2023, 16(1):159.
[18] Renzulli M, Pettinari I, Vasuri F, et al. Liver collision lesion: inflammatory hepatocellular adenoma within focal nodular hyperplasia. Gastroenterol Rep (Oxf), 2020, 9(4):374-376.
[19] Balabaud C, Laurent C, Le Bail B, et al. Unexpected discovery of small HNF1α-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumours. Liver Int, 2018, 38(7):1273-1279.
[20] Haddouche A, Bellanne-Chantelot C, Rod A, et al. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series. J Diabetes, 2020, 12(1):48-57.

Imaging feature of hepatocellular adenoma: An analysis of 39 cases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lai Zhenhui, Cai Yinlian, Cui Dong, et al. Prediction of esophageal gastric varices by abdominal CT scan parameters in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2026, 29(4): 565-568.
[2]	Chen Sumin, Wang Haixia, Jiang Kai, et al. MRI features impacting recurrence of tumor in patients with hepatocellular carcinoma after hepatectomy [J]. Journal of Practical Hepatology, 2026, 29(4): 593-596.
[3]	Liu Jianxiao, Wang Yan, Chen Shicheng, et al. CT-measured extracellular volume fraction in combination with serum NOX2 and YKL-40 levels in predicting hepatic fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2026, 29(3): 337-340.
[4]	Xu Xiaohu, Wang Wei, Ma Qiulian, et al. Application of MRI feature in combination with serum AFP and PIVKA-II levels in early diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(3): 405-408.
[5]	Wang Lifeng, Li Yan, Liu Cuicui, et al. Enhanced magnetic resonance imaging features of patients with biphenotypic hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(3): 409-412.
[6]	Wei Yumeng, Han Gaofei, Gao Pan. Enhanced CT texture parameters in predicting pathological tumor cell differentiation in patients with single-centered hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(3): 425-428.
[7]	Cheng Qi, Geng Chengjun, Jin Xiaofeng, et al. Differentiation diagnosis of atypical hepatic abscess and intrahepatic metastasis by MR with diffusion-weighted imaging [J]. Journal of Practical Hepatology, 2026, 29(3): 446-449.
[8]	Liu Jingfang, Hu Xiaojuan, Yang Weijian. MR imaging feature of focal nodular hyperplasia of liver: Analysis of 35 cases [J]. Journal of Practical Hepatology, 2026, 29(3): 454-457.
[9]	Ji Shengchao, Geng Chengjun, Lu Zehua, et al. Imaging manifestation clue for differential diagnosis of atypical hepatocellular carcinoma and mass intrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2026, 29(2): 281-284.
[10]	Shi Guofu, Zhu Zhitao, Zhang Supo, et al. MSCT and enhanced MRI in the differential diagnosis of focal nodular hyperplasia and hepatocellular carcinoma: Analysis of 108 cases [J]. Journal of Practical Hepatology, 2026, 29(2): 301-304.
[11]	Wang Wei, Meng Yun, Ji Peng. Quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging in the judgement of focal liver lesion quality: An preliminary study [J]. Journal of Practical Hepatology, 2026, 29(2): 305-308.
[12]	Yuan Weiwen, Liu Jinwu, Dong Ting, et al. MRI-proton density fat fraction in predicting liver steatosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2026, 29(1): 61-64.
[13]	Yao Liu, Liu Qi, Jiang Yilun, et al. T1 relaxation time of liver MRI in detecting portal hypertension in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(1): 89-92.
[14]	Song Lele, Chen Shunjun, Zhang Yabin. Dynamic contrast-enhanced MRI and diffusion-weighted imaging for assessing tumor viability following TACE in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(1): 117-120.
[15]	Wang Wei, Meng Yun, Ji Peng. Differential diagnosis of dysplastic nodule and small hepatocellular carcinoma under background of liver cirrhosis by enhanced magnetic resonance imaging [J]. Journal of Practical Hepatology, 2026, 29(1): 133-136.